Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic beta-cells or a reduction in beta-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on beta-cell physiology as well as by expanding or at least maintaining beta-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.

中文翻译：

---

靶向 2 型糖尿病中的 β 细胞群：基于肠促胰岛素的新药的前景和局限性。

由于胰腺 β 细胞功能异常或 β 细胞量减少，进行性胰岛素分泌缺陷是 2 型糖尿病的基石。基于肠促胰岛素的药物具有通过对 β 细胞生理学产生直接有利影响以及通过扩大或至少维持 β 细胞质量来改善葡萄糖耐量的潜力，这可能会延迟疾病的进展。需要对人类进行长期研究来详细说明这些影响。